Gingival epithelium provides first line of defence from the microorganisms present in dental plaque. It not only provides a mechanical barrier but also has an active immune function too. Gingival epithelial cells participate in innate immunity by producing a range of antimicrobial peptides to protect the host against oral pathogens. These epithelial antimicrobial peptides (EAPs) include the β-defensin family, cathelicidin (LL-37), calprotectin, and adrenomedullin. While some are constitutively expressed in gingival epithelial cells, others are induced upon exposure to microbial insults. It is likely that these EAPs have a role in determining the initiation and progression of oral diseases. EAPs are broad spectrum antimicrobials with a different but overlapping range of activity. Apart from antimicrobial activity, they participate in several other crucial roles in host tissues. Some of these, for instance, β-defensins, are chemotactic to immune cells. Others, such as calprotectin are important for wound healing and cell proliferation. Adrenomedullin, a multifunctional peptide, has its biological action in a wide range of tissues. Not only is it a potent vasodilator but also it has several endocrine effects. Knowing in detail the various bioactions of these EAPs may provide us with useful information regarding their utility as therapeutic agents. 1. Introduction Oral cavity is a diverse ecosystem where several microbes, commensal and pathogenic, interact and proliferate in the moist and warm environment. It is perhaps the only ecosystem of the human body which is dynamic, open, and close at the same time. The uniqueness of the oral cavity also lies in the presence of specialized interface which in the hard tissue (tooth) extrudes through the underlying soft tissue (gingival epithelium) [1]. The gingival epithelium constitutes oral epithelium, sulcular epithelium, and junctional epithelium. Since the tooth surface is invariably covered by a layer of microbial biofilm termed “dental plaque,” the surrounding epithelium is continuously exposed to microorganisms and their products [2]. The role of gingival epithelium has been under the scanner because of this close interaction. Previously considered to be an innocent bystander, its active role in host microbial interaction has been elucidated with recent research [3]. Gingival epithelium works in many ways for the protection of underlying connective tissue. First, it provides a physical barrier which does not allow microbes to invade while permitting selective transaction with oral environment. Second, upon
References
[1]
M. T. P？ll？nen, J. I. Salonen, and V.-J. Uitto, “Structure and function of the tooth-epithelial interface in health and disease,” Periodontology 2000, vol. 31, no. 1, pp. 12–31, 2003.
[2]
H. E. Schroeder and M. A. Listgarten, “The gingival tissues: The architecture of periodontal protection,” Periodontology 2000, vol. 14, no. 1, pp. 91–120, 1997.
[3]
M. S. Tonetti, “Molecular factors associated with compartmentalization of gingival immune responses and transepithelial neutrophil migration,” Journal of Periodontal Research, vol. 32, no. 1, pp. 104–109, 1997.
[4]
B. A. Dale, “Periodontal epithelium: A newly recognized role in health and disease,” Periodontology 2000, vol. 30, no. 1, pp. 70–78, 2002.
[5]
G. Diamond, N. Beckloff, and L. K. Ryan, “Host defense peptides in the oral cavity and the lung: similarities and differences,” Journal of Dental Research, vol. 87, no. 10, pp. 915–927, 2008.
[6]
T. Ganz, M. E. Selsted, D. Szklarek et al., “Defensins. Natural peptide antibiotics of human neutrophils,” The Journal of Clinical Investigation, vol. 76, no. 4, pp. 1427–1435, 1985.
[7]
F. G. Oppenheim, T. Xu, F. M. McMillian et al., “Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans,” Journal of Biological Chemistry, vol. 263, no. 16, pp. 7472–7477, 1988.
[8]
A. Weinberg, S. Krisanaprakornkit, and B. A. Dale, “Epithelial antimicrobial peptides: review and significance for oral applications,” Critical Reviews in Oral Biology and Medicine, vol. 9, no. 4, pp. 399–414, 1998.
[9]
H. G. Boman, “Cecropins : antibacterial peptides from insects and pigs,” in Phylogenetic Perspectives in Immunity: The Insect-Host Defense, J. Hoffmann, S. Natori, and C. Janeway, Eds., pp. 24–37, Landes Biomed, Austin, Tex, USA, 1994.
[10]
M. Zasloff, “Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 15, pp. 5449–5453, 1987.
[11]
D. Romeo, B. Skerlavaj, M. Bolognesi, and R. Gennaro, “Structure and bactericidal activity of an antibiotic dodecapeptide purified from bovine neutrophils,” Journal of Biological Chemistry, vol. 263, no. 20, pp. 9573–9575, 1988.
[12]
B. S. Schonwetter, E. D. Stolzenberg, and M. A. Zasloff, “Epithelial antibiotics induced at sites of inflammation,” Science, vol. 267, no. 5204, pp. 1645–1648, 1995.
[13]
B. A. Dale and S. Krisanaprakornkit, “Defensin antimicrobial peptides in the oral cavity,” Journal of Oral Pathology and Medicine, vol. 30, no. 6, pp. 321–327, 2001.
[14]
M. Mathews, H. P. Jia, J. M. Guthmiller et al., “Production of β-defensin antimicrobial peptides by the oral mucosa and salivary glands,” Infection and Immunity, vol. 67, no. 6, pp. 2740–2745, 1999.
[15]
G. Diamond, M. Zasloff, H. Eck, M. Brasseur, W. Lee Maloy, and C. L. Bevins, “Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 9, pp. 3952–3956, 1991.
[16]
B. L. Kagan, T. Ganz, and R. I. Lehrer, “Defensins: a family of antimicrobial and cytotoxic peptides,” Toxicology, vol. 87, no. 1–3, pp. 131–149, 1994.
[17]
Y. Abiko, M. Saitoh, M. Nishimura, M. Yamazaki, D. Sawamura, and T. Kaku, “Role of β-defensins in oral epithelial health and disease,” Medical Molecular Morphology, vol. 40, no. 4, pp. 179–184, 2007.
[18]
B. A. Dale, J. R. Kimball, S. Krisanaprakornkit et al., “Localized antimicrobial peptide expression in human gingiva,” Journal of Periodontal Research, vol. 36, no. 5, pp. 285–294, 2001.
[19]
Q. Lu, L. P. Samaranayake, R. P. Darveau, and L. Jin, “Expression of human β-defensin-3 in gingival epithelia,” Journal of Periodontal Research, vol. 40, no. 6, pp. 474–481, 2005.
[20]
S. Krisanaprakornkit, A. Weinberg, C. N. Perez, and B. A. Dale, “Expression of the peptide antibiotic human β-defensin 1 in cultured gingival epithelial cells and gingival tissue,” Infection and Immunity, vol. 66, no. 9, pp. 4222–4228, 1998.
[21]
P. Premratanachai, S. Joly, G. K. Johnson, P. B. McCray Jr., H. P. Jia, and J. M. Guthmiller, “Expression and regulation of novel human β-defensins in gingival keratinocytes,” Oral Microbiology and Immunology, vol. 19, no. 2, pp. 111–117, 2004.
[22]
K. W. Bensch, M. Raida, H. J. M？gert, P. Schulz-Knappe, and W. G. Forssmann, “hBD-1: a novel β-defensin from human plasma,” FEBS Letters, vol. 368, no. 2, pp. 331–335, 1995.
[23]
L. Liu, C. Zhao, H. H. Q. Heng, and T. Ganz, “The human β-defensin-1 and α-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry,” Genomics, vol. 43, no. 3, pp. 316–320, 1997.
[24]
T. Ganz, “Defensins: antimicrobial peptides of innate immunity,” Nature Reviews Immunology, vol. 3, no. 9, pp. 710–720, 2003.
[25]
J. Harder, J. Bartels, E. Christophers, and J. M. Schr？der, “A peptide antibiotic from human skin,” Nature, vol. 387, no. 6636, p. 861, 1997.
[26]
J. Harder, R. Siebert, Y. Zhang et al., “Mapping of the gene encoding human β-defensin-2 (DEFB2) to chromosome region 8p22-p23.1,” Genomics, vol. 46, no. 3, pp. 472–475, 1997.
[27]
H. P. Jia, B. C. Schutte, A. Schudy, et al., “Discovery of new human β-defensins using a genomics-based approach,” Gene, vol. 263, no. 1-2, pp. 211–218, 2001.
[28]
J. Harder, J. Bartels, E. Christophers, and J.-M. Schr？der, “Isolation and characterization of human betadefensin-3, a novel human inducible peptide antibiotic,” The Journal of Biological Chemistry, vol. 276, no. 8, pp. 5707–5713, 2001.
[29]
S. Offenbacher, S. P. Barros, D. W. Paquette, et al., “Gingival transcriptome patterns during induction and resolution of experimental gingivitis in humans,” Journal of Periodontology, vol. 80, no. 12, pp. 1963–1982, 2009.
[30]
Q. Lu, L. Jin, R. P. Darveau, and L. P. Samaranayake, “Expression of human β-defensins-1 and -2 peptides in unresolved chronic periodontitis,” Journal of Periodontal Research, vol. 39, no. 4, pp. 221–227, 2004.
[31]
G. Diamond, N. Beckloff, A. Weinberg, and K. O. Kisich, “The roles of antimicrobial peptides in innate host defense,” Current Pharmaceutical Design, vol. 15, no. 21, pp. 2377–2392, 2009.
[32]
H. R. Conti, F. Shen, N. Nayyar et al., “Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis,” Journal of Experimental Medicine, vol. 206, no. 2, pp. 299–311, 2009.
[33]
M. E. Selsted, Y.-Q. Tang, W. L. Morris et al., “Purification, primary structures, and antibacterial activities of β-defensins, a new family of antimicrobial peptides from bovine neutrophils,” The Journal of Biological Chemistry, vol. 268, no. 9, pp. 6641–6648, 1993.
[34]
M. S. Gardner, M. D. Rowland, A. Y. Siu, J. L. Bundy, D. K. Wagener, and J. L. Stephenson Jr., “Comprehensive defensin assay for Saliva,” Analytical Chemistry, vol. 81, no. 2, pp. 557–566, 2009.
[35]
R. Tao, R. J. Jurevic, K. K. Coulton et al., “Salivary antimicrobial peptide expression and dental caries experience in children,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 9, pp. 3883–3888, 2005.
[36]
S. Joly, C. Maze, P. B. McCray Jr., and J. M. Guthmiller, “Human β- defensins 2 and demonstrate strain selective activity against oral microorganisms,” Journal of Clinical Microbiology, vol. 42, no. 3, pp. 1024–1029, 2004.
[37]
S. Ji, J. Hyun, E. Park, B.-L. Lee, K.-K. Kim, and Y. Choi, “Susceptibility of various oral bacteria to antimicrobial peptides and to phagocytosis by neutrophils,” Journal of Periodontal Research, vol. 42, no. 5, pp. 410–419, 2007.
[38]
Z. Feng, B. Jiang, J. Chandra, M. Ghannoum, S. Nelson, and A. Weinberg, “Human beta-defensins: differential activity against candidal species and regulation by Candida albicans,” Journal of Dental Research, vol. 84, no. 5, pp. 445–450, 2005.
[39]
Z. Feng, G. R. Dubyak, M. M. Lederman, and A. Weinberg, “Cutting edge: human defensin 3—a novel antagonist of the HIV-1 coreceptor CXCR4,” The Journal of Immunology, vol. 177, no. 2, pp. 782–786, 2006.
[40]
S. Ji, J. E. Shin, Y. C. Kim, and Y. Choi, “Intracellular degradation of Fusobacterium nucleatum in human gingival epithelial cells,” Molecules and Cells, vol. 30, no. 6, pp. 519–526, 2010.
[41]
K. Ouhara, H. Komatsuzawa, S. Yamada et al., “Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL37, produced by human epithelial cells,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 6, pp. 888–896, 2005.
[42]
C. E. Shelburne, W. A. Coulter, D. Olguin, M. S. Lantz, and D. E. Lopatin, “Induction of β-defensin resistance in the oral anaerobe Porphyromonas gingivalis,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 1, pp. 183–187, 2005.
[43]
J. E. Shin and Y. Choi, “Treponema denticola suppresses expression of human β-defensin-2 in gingival epithelial cells through inhibition of TNFα production and TLR2 activation,” Molecules and cells, vol. 29, no. 4, pp. 407–412, 2010.
[44]
Y. Agawa, S. Lee, S. Ono et al., “Interaction with phospholipid bilayers, ion channel formation, and antimicrobial activity of basic amphipathic α-helical model peptides of various chain lengths,” Journal of Biological Chemistry, vol. 266, no. 30, pp. 20218–20222, 1991.
[45]
A. M. Cole, T. Ganz, A. M. Liese, M. D. Burdick, L. Liu, and R. M. Strieter, “Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity,” Journal of Immunology, vol. 167, no. 2, pp. 623–627, 2001.
[46]
D. Yang, A. Biragyn, L. W. Kwak, and J. J. Oppenheim, “Mammalian defensins in immunity: more than just microbicidal,” Trends in Immunology, vol. 23, no. 6, pp. 291–296, 2002.
[47]
D. Yang, O. Chertov, S. N. Bykovskaia, et al., “β-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6,” Science, vol. 286, no. 5439, pp. 525–528, 1999.
[48]
F. Niyonsaba, H. Ogawa, and I. Nagaoka, “Human β-defensin-2 functions as a chemotactic agent for tumour necrosis factor-α-treated human neutrophils,” Immunology, vol. 111, no. 3, pp. 273–281, 2004.
[49]
F. Niyonsaba, A. Someya, M. Hirata, H. Ogawa, and I. Nagaoka, “Evaluation of the effects of peptide antibiotics human -defensins-1/-2 and LL-37 on histamine release and prostaglandin D2 production from mast cells,” European Journal of Immunology, vol. 31, no. 4, pp. 1066–1075, 2001.
[50]
F. Niyonsaba, H. Ushio, N. Nakano et al., “Antimicrobial peptides human β-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines,” Journal of Investigative Dermatology, vol. 127, no. 3, pp. 594–604, 2007.
[51]
K. G. Kohlgraf, L. C. Pingel, D. E. Dietrich, and K. A. Brogden, “Defensins as anti-inflammatory compounds and mucosal adjuvants,” Future Microbiology, vol. 5, no. 1, pp. 99–113, 2010.
[52]
F. Semple, S. Webb, H.-N. Li et al., “Human β-defensin 3 has immunosuppressive activity in vitro and in vivo,” European Journal of Immunology, vol. 40, no. 4, pp. 1073–1078, 2010.
[53]
O. E. Sorensen, J. B. Cowland, K. Theilgaard-M？nch, L. Liu, T. Ganz, and N. Borregaard, “Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors,” The Journal of Immunology, vol. 170, no. 11, pp. 5583–5589, 2003.
[54]
D. Yang, A. Biragyn, D. M. Hoover, J. Lubkowski, and J. J. Oppenheim, “Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense,” Annual Review of Immunology, vol. 22, pp. 181–215, 2004.
[55]
B. Ramanathan, E. G. Davis, C. R. Ross, and F. Blecha, “Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity,” Microbes and Infection, vol. 4, no. 3, pp. 361–372, 2002.
[56]
M. Zaiou and R. L. Gallo, “Cathelicidins, essential gene-encoded mammalian antibiotics,” Journal of Molecular Medicine, vol. 80, no. 9, pp. 549–561, 2002.
[57]
R. Gennaro and M. Zanetti, “Structural features and biological activities of the cathelicidin-derived antimicrobial peptides,” Biopolymers, vol. 55, pp. 31–49, 2000.
[58]
G. H. Gudmundsson, B. Agerberth, J. Odeberg, T. Bergman, B. Olsson, and R. Salcedo, “The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes,” European Journal of Biochemistry, vol. 238, no. 2, pp. 325–332, 1996.
[59]
J. W. Larrick, M. Hirata, R. F. Balint, J. Lee, J. Zhong, and S. C. Wright, “Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein,” Infection and Immunity, vol. 63, no. 4, pp. 1291–1297, 1995.
[60]
M. F. Nilsson, B. Sandstedt, O. S？rensen, G. Weber, N. Borregaard, and M. Stahle-Backdahl, “The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6,” Infection and Immunity, vol. 67, no. 5, pp. 2561–2566, 1999.
[61]
M. Murakami, T. Ohtake, R. A. Dorschner, and R. L. Gallo, “Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva,” Journal of Dental Research, vol. 81, no. 12, pp. 845–850, 2002.
[62]
O. Turkoglu, G. Emingil, N. Kutuk？uler, and G. Atilla, “Gingival crevicular fluid levels of cathelicidin ll-37 and interleukin-18 in patients with chronic periodontitis,” Journal of Periodontology, vol. 80, no. 6, pp. 969–976, 2009.
[63]
I. Hosokawa, Y. Hosokawa, H. Komatsuzawa et al., “Innate immune peptide LL-37 displays distinct expression pattern from beta-defensins in inflamed gingival tissue,” Clinical and Experimental Immunology, vol. 146, no. 2, pp. 218–225, 2006.
[64]
M. Zanetti, R. Gennaro, M. Scocchi, and B. Skerlavaj, “Structure and biology of cathelicidins,” Advances in Experimental Medicine and Biology, vol. 479, pp. 203–218, 2000.
[65]
O. E. Sorensen, J. B. Cowland, K. Theilgaard-M？nch, L. Liu, T. Ganz, and N. Borregaard, “Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors,” Journal of Immunology, vol. 170, no. 11, pp. 5583–5589, 2003.
[66]
G. Weber, J. D. Heilborn, C. I. C. Jimenez, A. Hammarsj？, H. T？rm？, and M. St？hle, “Vitamin D induces the antimicrobial protein hCAP18 in human skin,” Journal of Investigative Dermatology, vol. 124, no. 5, pp. 1080–1082, 2005.
[67]
O. Türko？lu, G. Emingil, N. Kütükcxüler, and G. Atilla, “Gingival crevicular fluid levels of cathelicidin ll-37 and interleukin-18 in patients with chronic periodontitis,” Journal of Periodontology, vol. 80, no. 6, pp. 969–976, 2009.
[68]
A. Panyutich, J. Shi, P. L. Boutz, C. Zhao, and T. Ganz, “Porcine polymorphonuclear leukocytes generate extracellular microbicidal activity by elastase-mediated activation of secreted proprotegrins,” Infection and Immunity, vol. 65, no. 3, pp. 978–985, 1997.
[69]
O. E. Sorensen, P. Follin, A. H. Johnsen et al., “Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3,” Blood, vol. 97, no. 12, pp. 3951–3959, 2001.
[70]
V. Nizet and R. L. Gallo, “Cathelicidins and innate defense against invasive bacterial infection,” Scandinavian Journal of Infectious Diseases, vol. 35, no. 9, pp. 670–676, 2003.
[71]
G. Bachrach, G. Chaushu, M. Zigmond et al., “Salivary LL-37 secretion in individuals with down syndrome is normal,” Journal of Dental Research, vol. 85, no. 10, pp. 933–936, 2006.
[72]
M. Gutner, S. Chaushu, D. Balter, and G. Bachrach, “Saliva enables the antimicrobial activity of LL-37 in the presence of proteases of Porphyromonas gingivalis,” Infection and Immunity, vol. 77, no. 12, pp. 5558–5563, 2009.
[73]
M. Inomata, T. Into, and Y. Murakami, “Suppressive effect of the antimicrobial peptide LL-37 on expression of IL-6, IL-8 and CXCL10 induced by Porphyromonas gingivalis cells and extracts in human gingival fibroblasts,” European Journal of Oral Sciences, vol. 118, no. 6, pp. 574–581, 2010.
[74]
K. Pütsep, G. Carlsson, H. G. Boman, and M. Andersson, “Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study,” The Lancet, vol. 360, no. 9340, pp. 1144–1149, 2002.
[75]
Z. Oren and Y. Shai, “Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: structure-function study,” Biochemistry, vol. 36, no. 7, pp. 1826–1835, 1997.
[76]
O. Chertov, D. F. Michiel, L. Xu et al., “Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils,” Journal of Biological Chemistry, vol. 271, no. 6, pp. 2935–2940, 1996.
[77]
D. Yang and J. J. Oppenheim, “Alarmins and antimicrobial immunity,” Medical Mycology, vol. 47, pp. S146–S153, 2009.
[78]
C. Pr？pper, X. Huang, J. Roth, C. Sorg, and W. Nacken, “Analysis of the MRP8-MRP14 protein-protein interaction by the two- hybrid system suggests a prominent role of the C-terminal domain of S100 proteins in dimer formation,” Journal of Biological Chemistry, vol. 274, no. 1, pp. 183–188, 1999.
[79]
J. R. Dorin, M. Novak, R. E. Hill, D. J. Brock, D. S. Secher, and V. van Heyningen, “A clue to the basic defect in cystic fibrosis from cloning the CF antigen gene,” Nature, vol. 326, no. 6113, pp. 614–617, 1987.
[80]
I. Dale, P. Brandtzaeg, M. K. Fagerhol, and H. Scott, “Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin,” The American Journal of Clinical Pathology, vol. 84, no. 1, pp. 24–34, 1985.
[81]
K. Odink, N. Cerletti, J. Bruggen et al., “Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis,” Nature, vol. 330, no. 6143, pp. 80–82, 1987.
[82]
P. Brandtzaeg, I. Dale, and M. K. Fagerhol, “Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. II. Normal and aberrant occurrence in various epithelia,” The American Journal of Clinical Pathology, vol. 87, no. 6, pp. 700–707, 1987.
[83]
J. Sander, M. K. Fagerhol, J. S. Bakken, and I. Dale, “Plasma levels of the leucocyte L1 protein in febrile conditions: relation to aetiology, number of leucocytes in blood, blood sedimentation reaction and C-reactive protein,” Scandinavian Journal of Clinical & Laboratory Investigation, vol. 44, no. 4, pp. 357–362, 1984.
[84]
M. Cuida, A.-K. Halse, A. C. Johannessen, T. Tynning, and R. Jonsson, “Indicators of salivary gland inflammation in primary Sj？gren's syndrome,” European Journal of Oral Sciences, vol. 105, no. 3, pp. 228–233, 1997.
[85]
H. B. Hammer, T. K. Kvien, A. Glennas, and K. Melby, “A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis,” Clinical and Experimental Rheumatology, vol. 13, no. 1, pp. 59–64, 1995.
[86]
C. Marionnet, F. Bernerd, A. Dumas et al., “Modulation of gene expression induced in human epidermis by environmental stress in vivo,” Journal of Investigative Dermatology, vol. 121, no. 6, pp. 1447–1458, 2003.
[87]
S. G. Gregory, K. F. Barlow, K. E. McLay et al., “The DNA sequence and biological annotation of human chromosome 1,” Nature, vol. 441, pp. 315–321, 2006.
[88]
C. Kerkhoff, M. Klempt, and C. Sorg, “Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9),” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1448, no. 2, pp. 200–211, 1998.
[89]
D. Benet Bosco Dhas, B. Vishnu Bhat, and D. Bahubali Gane, “Role of calprotectin in infection and inflammation,” Current Pediatric Research, vol. 16, no. 2, pp. 83–94, 2012.
[90]
J.-I. Kido, T. Nakamura, R. Kido et al., “Calprotectin in gingival crevicular fluid correlates with clinical and biochemical markers of periodontal disease,” Journal of Clinical Periodontology, vol. 26, no. 10, pp. 653–657, 1999.
[91]
T. Nakamura, J.-I. Kido, R. Kido et al., “The association of calprotectin level in gingival crevicular fluid with gingival index and the activities of collagenase and aspartate aminotransferase in adult periodontitis patients,” Journal of Periodontology, vol. 71, no. 3, pp. 361–367, 2000.
[92]
R. S. Gómez, P. Langer, M. Pelka, P. von den Driesch, A. C. Johannessen, and M. Simon Jr., “Variational expression of functionally different macrophage markers (27E10, 25F9, RM3/1) in normal gingiva and inflammatory periodontal disease,” Journal of Clinical Periodontology, vol. 22, no. 5, pp. 341–346, 1995.
[93]
P. A. Hessian, J. Edgeworth, and N. Hogg, “MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes,” Journal of Leukocyte Biology, vol. 53, no. 2, pp. 197–204, 1993.
[94]
C. W. Heizmann, G. Fritz, and B. W. Sch？fer, “S100 proteins: structure, functions and pathology,” Frontiers in Bioscience, vol. 7, pp. d1356–d1368, 2002.
[95]
M. Cuida, J. G. Brun, T. Tynning, and R. Jonsson, “Calprotectin levels in oral fluids: the importance of collection site,” European Journal of Oral Sciences, vol. 103, no. 1, pp. 8–10, 1995.
[96]
M. Steinbakk, C.-F. Naess-Andresen, E. Lingaas, I. Dale, P. Brandtzaeg, and M. K. Fagerhol, “Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin,” The Lancet, vol. 336, no. 8718, pp. 763–765, 1990.
[97]
K. Nisapakultorn, K. F. Ross, and M. C. Herzberg, “Calprotectin expression in vitro by oral epithelial cells confers resistance to infection by Porphyromonas gingivalis,” Infection and Immunity, vol. 69, no. 7, pp. 4242–4247, 2001.
[98]
A. R. K. Murthy, R. I. Lehrer, S. S. L. Harwig, and K. T. Miyasaki, “In vitro candidastatic properties of the human neutrophil calprotectin complex,” Journal of Immunology, vol. 151, no. 11, pp. 6291–6301, 1993.
[99]
L. R. Eversole, K. T. Miyasaki, and R. E. Christensen, “Keratinocyte expression of calprotectin in oral inflammatory mucosal diseases,” Journal of Oral Pathology and Medicine, vol. 22, no. 7, pp. 303–307, 1993.
[100]
S. M. Damo, T. E. Kehl-Fie, N. Sugitani et al., “Molecular basis for manganese sequestration by calprotectin and roles in the innate immune response to invading bacterial pathogens,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 10, pp. 3841–3846, 2013.
[101]
P. Brandtzaeg, T.-O. Gabrielsen, I. Dale, F. Muller, M. Steinbakk, and M. K. Fagerhol, “The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces,” Advances in Experimental Medicine and Biology, vol. 371, pp. 201–206, 1995.
[102]
D. B. Zimmer, J. O. Eubanks, D. Ramakrishnan, and M. F. Criscitiello, “Evolution of the S100 family of calcium sensor proteins,” Cell Calcium, vol. 53, no. 3, pp. 170–179, 2013.
[103]
C. Kerkhoff, A. Voss, T. E. Scholzen, M. M. Averill, K. S. Z？nker, and K. E. Bornfeldt, “Novel insights into the role of S100A8/A9 in skin biology,” Experimental Dermatology, vol. 21, no. 11, pp. 822–826, 2012.
[104]
W. Nacken, J. Roth, C. Sorg, and C. Kerkhoff, “S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity,” Microscopy Research and Technique, vol. 60, no. 6, pp. 569–580, 2003.
[105]
A. González-López, A. Aguirre, I. López-Alonso et al., “MMP-8 deficiency increases TLR/RAGE ligands S100A8 and S100A9 and exacerbates lung inflammation during endotoxemia,” PLoS ONE, vol. 7, no. 6, Article ID e39940, 2012.
[106]
K. Kitamura, K. Kangawa, M. Kawamoto et al., “Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma,” Biochemical and Biophysical Research Communications, vol. 192, no. 2, pp. 553–560, 1993.
[107]
B. Cheung and R. Leung, “Elevated plasma levels of human adrenomedullin in cardiovascular, respiratory, hepatic and renal disorders,” Clinical Science, vol. 92, no. 1, pp. 59–62, 1997.
[108]
T. Hata, K. Miyazaki, and K. Matsui, “Decreased circulating adrenomedullin in preeclampsia,” The Lancet, vol. 350, no. 9091, p. 1600, 1997.
[109]
K. Kitamura, J. Sakata, K. Kangawa, M. Kojima, H. Matsuo, and T. Eto, “Cloning and characterization of cDNA encoding a precursor for human adrenomedullin,” Biochemical and Biophysical Research Communications, vol. 194, no. 2, pp. 720–725, 1993.
[110]
R. P. Allaker, C. Zihni, and S. Kapas, “An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microflora,” FEMS Immunology and Medical Microbiology, vol. 23, no. 4, pp. 289–293, 1999.
[111]
T. Ishimitsu, M. Kojima, K. Kangawa et al., “Genomic structure of human adrenomedullin gene,” Biochemical and Biophysical Research Communications, vol. 203, no. 1, pp. 631–639, 1994.
[112]
B. Gumusel, J.-K. Chang, A. Hyman, and H. Lippton, “Adrenotensin: an ADM gene product with the opposite effects of ADM,” Life Sciences, vol. 57, no. 8, pp. PL87–PL90, 1995.
[113]
S. Kapas, A. Bansal, V. Bhargava et al., “Adrenomedullin expression in pathogen-challenged oral epithelial cells,” Peptides, vol. 22, no. 9, pp. 1485–1489, 2001.
[114]
S. Kapas, M. Luisa Tenchini, and P. M. Farthing, “Regulation of adrenomedullin secretion in cultured human skin and oral keratinocytes,” Journal of Investigative Dermatology, vol. 117, no. 2, pp. 353–359, 2001.
[115]
S. Kapas, K. Pahal, A. T. Cruchley, E. Hagi-Pavli, and J. P. Hinson, “Expression of adrenomedullin and its receptors in human salivary tissue,” Journal of Dental Research, vol. 83, no. 4, pp. 333–337, 2004.
[116]
R. P. Allaker, P. W. Grosvenor, D. C. McAnerney et al., “Mechanisms of adrenomedullin antimicrobial action,” Peptides, vol. 27, no. 4, pp. 661–666, 2006.
[117]
H. He, H. Bessho, Y. Fujisawa et al., “Effects of a synthetic rat adrenomedullin on regional hemodynamics in rats,” European Journal of Pharmacology, vol. 273, no. 3, pp. 209–214, 1995.
[118]
A. Friedman, L. Todd, R. S. Baker, and K. E. Clark, “Uterine vascular effects of adrenomedullin,” Journal of the Society for Gynecologic Investigation, vol. 5, p. F449, 1998.
[119]
W. K. Samson, T. Murphy, and D. A. Schell, “A novel vasoactive peptide, adrenomedullin, inhibits pituitary adrenocorticotropin release,” Endocrinology, vol. 136, no. 5, pp. 2349–2352, 1995.
[120]
G. G. Nussdorfer, “Paracrine control of adrenal cortical function by medullary chromaffin cells,” Pharmacological Reviews, vol. 48, no. 4, pp. 495–530, 1996.
[121]
A. Martínez, C. Weaver, J. López et al., “Regulation of insulin secretion and blood glucose metabolism by adrenomedullin,” Endocrinology, vol. 137, no. 6, pp. 2626–2632, 1996.
[122]
J. J. Cebra, “Influences of microbiota on intestinal immune system development,” The American Journal of Clinical Nutrition, vol. 69, no. 5, pp. 1046S–1051S, 1999.
[123]
L. V. Hooper, M. H. Wong, A. Thelin, L. Hansson, P. G. Falk, and J. I. Gordon, “Molecular analysis of commensal host-microbial relationships in the intestine,” Science, vol. 291, no. 5505, pp. 881–884, 2001.
[124]
S. K. Mazmanian, H. L. Cui, A. O. Tzianabos, and D. L. Kasper, “An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system,” Cell, vol. 122, no. 1, pp. 107–118, 2005.
[125]
G. Reid, J. Jass, M. T. Sebulsky, and J. K. McCormick, “Potential uses of probiotics in clinical practice,” Clinical Microbiology Reviews, vol. 16, no. 4, pp. 658–672, 2003.
[126]
W. O. Chung and B. A. Dale, “Innate immune response of oral and foreskin keratinocytes: utilization of different signaling pathways by various bacterial species,” Infection and Immunity, vol. 72, no. 1, pp. 352–358, 2004.
[127]
Y. Hasegawa, J. J. Mans, S. Mao et al., “Gingival epithelial cell transcriptional responses to commensal and opportunistic oral microbial species,” Infection and Immunity, vol. 75, no. 5, pp. 2540–2547, 2007.
[128]
A. S. Neish, A. T. Gewirtz, H. Zeng et al., “Prokaryotic regulation of epithelial responses by inhibition of IκB-α ubiquitination,” Science, vol. 289, no. 5484, pp. 1560–1563, 2000.
[129]
S. Rakoff-Nahoum, J. Paglino, F. Eslami-Varzaneh, S. Edberg, and R. Medzhitov, “Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis,” Cell, vol. 118, no. 2, pp. 229–241, 2004.
[130]
M.-T. Tien, S. E. Girardin, B. Regnault et al., “Antiinflammatory effect of Lactobacillus casei on Shigella -infected human intestinal epithelial cells,” Journal of Immunology, vol. 176, no. 6, pp. 1228–1237, 2006.
[131]
C. Grangette, S. Nutten, E. Palumbo et al., “Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 29, pp. 10321–10326, 2005.
[132]
C. Cosseau, D. A. Devine, E. Dullaghan et al., “The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis,” Infection and Immunity, vol. 76, no. 9, pp. 4163–4175, 2008.
[133]
F. J. Giles, C. B. Miller, D. D. Hurd, et al., “A phase III, randomized, double-blind, placebo-controlled, multinational trial of Iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT Trial),” Leukemia & Lymphoma, vol. 44, no. 7, pp. 1165–1172, 2003.
[134]
S. Elad, J. B. Epstein, J. Raber-Durlacher, P. Donnelly, and J. Strahilevitz, “The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial,” Journal of Oral Pathology & Medicine, vol. 41, no. 3, pp. 229–234, 2012.
